7.2.2　Apatinib

Apatinib is a self-developed target for the target VEGFR-2 TKI.October 17，2014，approved by CFDA for advanced gastric cancer or gastroesophageal junction adenocarcinoma three-line and thirdline treatment.In addition to gastric cancer In the field，apatinib has also achieved good results in other cancers such as breast cancer and liver cancer.In 2017，the American Society of Oncology（ASCO）demonstrated the efficacy of oral vinorelbine plus apatinib in advanced breast cancer.This prospective phase Ⅱ clinical study included advanced breast cancer patients with HER-2 negative transanthology or yew first-line treatment，and plans to enroll 40 patients.At the 2017 Global Breast Cancer Congress（GBCC），the study of apatinib combined with chemotherapy led by Professor Yuan Wei was applied to the study of metastatic breast cancer after multi-line treatment.The study enrolled 23 patients with metastatic breast cancer who had progressed after at least one line of treatment.Among which，14（60.9%）received a chemotherapy regimen containing plants and 9（39.1%）received a non-plant drug regimen.The results of the study showed that the ORR was 34.7%and the median PFS was 5.4 months（95%CI：3.5～7.3 months），the median OS is 8.2 months（95%CI：4.7 to 11.7 months）.Adverse reactions are tolerated and effectively controlled.The most common are hypertension，myelosuppression，hand-foot syndrome，proteinuria，fatigue，and gastrointestinal reactions.The most common grade 3～4 adverse events are myelosuppression（39.1%）and gastrointestinal reactions（17.4%）.This study did not interfere with the clinician's medication decision，indicating that apatinib combined with chemotherapy for advanced breast cancer failure after multi-line treatment can achieve significant efficacy，adverse reactions can be tolerant and controllable.(https://www.daowen.com)